At the 2025 American Academy of Neurology (AAN) Annual Meeting, argenx presented key results from Part B of the ADAPT-NXT study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase) in patients with generalized myasthenia gravis (gMG). The trial investigated two subcutaneous dosing regimens—every two weeks and every three weeks—both of which demonstrated rapid and sustained clinical improvements starting as early as Week 1. Primary endpoints included changes in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score and Quantitative Myasthenia Gravis (QMG) score, both of which showed statistically significant improvements compared to baseline. Safety results were consistent with prior Vyvgart studies, with injection-site reactions and mild infections being the most commonly reported adverse events. The findings confirm that Vyvgart Hytrulo, an on-body subcutaneous formulation, maintains the rapid onset and durability seen with intravenous Vyvgart, while offering more flexible administration. These data support the broader use of Vyvgart Hytrulo as a patient-centric treatment option for gMG and may position it favorably against competing FcRn blockers, especially given its proven efficacy in both AChR and MuSK antibody-positive populations.

Citation: https://www.argenx.com/news/argenx-presents-new-adapt-nxt-data-aan-2025-demonstrating-rapid-and-sustained-clinical-benefit-of-vyvgart-hytrulo-in-mg

Implication: Positive ADAPT-NXT findings support expanded adoption of Vyvgart Hytrulo, reinforcing its competitive edge through flexible dosing and rapid efficacy.